Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Translational Therapeutics

Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer

British Journal of Cancer volume 128, pages 1603–1608 (2023)Cite this article

Subjects

Abstract

Background

Liquid biopsy is an alternative to tissue specimens for tumour genotyping. However, the frequency of genomic alterations with low circulating-tumour DNA (ctDNA) shedding is shown in pancreatic ductal adenocarcinoma (PDAC). We, therefore, investigated the prevalence of KRAS mutations and ctDNA fraction by the metastatic site in patients with PDAC.

Methods

This study enrolled previously treated PDAC patients from a plasma genomic profiling study; ctDNA analysis was performed using Guardant360 at disease progression before initiating subsequent treatment.

Results

In 512 patients with PDAC, KRAS mutations were detected in 57%. The frequency of KRAS mutation in ctDNA differed depending on the metastatic organ; among patients with single-organ metastasis (n = 296), KRAS mutation detection rate was significantly higher in patients with metastasis to the liver (78%). In addition, the median maximum variant allele frequency (VAF) was higher with metastasis to the liver (1.9%) than with metastasis to the lungs, lymph nodes, peritoneum or with locally advanced disease (0.2%, 0.4%, 0.2% and 0.3%, respectively).

Conclusion

The prevalence of KRAS mutations and maximum VAF were higher in patients with metastasis to the liver than in those with metastasis to other sites. This study indicated the clinical utility of ctDNA analysis, especially in PDAC with liver metastases.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Genomic alterations identified with ctDNA analysis in patients with PDAC.
Fig. 2: The maximum VAF (%) and frequencies of the detection of KRAS mutation in ctDNA in patients with metastasis to a single site (n = 296).

Similar content being viewed by others

Data availability

The authors declare that all variant data used in the conduct of the analyses are available within the article and its Supplementary information. To protect the privacy and confidentiality of patients in this study, clinical data are not made publicly available in a repository or the supplementary material of the article but will be made available following reasonable request to the corresponding author.

References

  1. Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Investig. 2012;122:639–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology. 2019;156:2242–53.e4

    Article  CAS  PubMed  Google Scholar 

  3. Tempero MA. NCCN guidelines updates: pancreatic cancer. J Natl Compr Cancer Netw: JNCCN. 2019;17:603–5.

    CAS  PubMed  Google Scholar 

  4. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, et al. Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci. 2019;110:1480–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 2015;5:1040–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 2020;26:1859–64.

    Article  CAS  PubMed  Google Scholar 

  9. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, et al. Circulating tumor DNA detection by digital-droplet PCR in pancreatic ductal adenocarcinoma: a systematic review. Cancers. 2021;13:994.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin Cancer Res. 2018;24:3539–49.

    Article  CAS  PubMed  Google Scholar 

  11. Bando H, Nakamura Y, Taniguchi H, Shiozawa M, Yasui H, Esaki T, et al. Impact of a metastatic site on circulating tumor DNA (ctDNA) analysis in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39:3554.

    Article  Google Scholar 

  12. Ako S, Nouso K, Kinugasa H, Dohi C, Matushita H, Mizukawa S, et al. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Pancreatology. 2017;17:285–90.

    Article  CAS  PubMed  Google Scholar 

  13. Watanabe F, Suzuki K, Tamaki S, Abe I, Endo Y, Takayama Y, et al. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS ONE. 2019;14:e0227366.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Patel H, Okamura R, Fanta P, Patel C, Lanman RB, Raymond VM, et al. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol. 2019;12:130.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10:1842–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank all of the patients and their families who participated in this study; all investigators and site personnel; Translational Research Support Section; Y Sakamoto and M Hata (National Cancer Center Hospital East) for data management; and all the National Cancer Center Hospital East Translational Research Support Section members.

Funding

This work was supported by SCRUM-Japan Funds (http://www.scrum-japan.ncc.go.jp/index.html).

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan

    Kumiko Umemoto & Yu Sunakawa

  2. Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan

    Makoto Ueno

  3. Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

    Masayuki Furukawa

  4. Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan

    Nobumasa Mizuno

  5. Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan

    Kentaro Sudo

  6. Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan

    Yasuyuki Kawamoto

  7. Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan

    Takeshi Kajiwara

  8. Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

    Koushiro Ohtsubo

  9. Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan

    Naohiro Okano

  10. Department of Gastroenterological Surgery, Gifu University, Gifu, Japan

    Nobuhisa Matsuhashi

  11. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Shinji Itoh

  12. Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan

    Toshihiko Matsumoto

  13. Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan

    Satoshi Shimizu

  14. Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan

    Toru Otsuru

  15. Department of Gastroenterology and Hepatology, National Hospital Organization, Osaka National Hospital, Osaka, Japan

    Hiroko Hasegawa

  16. Department of Clinical Oncology, Kagawa University, Kagawa, Japan

    Hiroyuki Okuyama

  17. Department of Gastroenterology, Osaka Medical College, Osaka, Japan

    Hideko Ohama

  18. Department of Gastroenterology, University of Tsukuba Hospital, Tsukuba, Japan

    Toshikazu Moriwaki

  19. Department of Clinical Oncology, Kansai Rosai Hospital, Hyogo, Japan

    Takashi Ohta

  20. Guardant Health, Redwood City, CA, USA

    Justin I. Odegaard

  21. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan

    Yoshiaki Nakamura, Hideaki Bando & Takayuki Yoshino

  22. Translational Research Support Section, National Cancer Center Hospital East, Kashiwa, Japan

    Yoshiaki Nakamura

  23. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan

    Masafumi Ikeda

  24. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

    Chigusa Morizane

Authors
  1. Kumiko Umemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Sunakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Makoto Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masayuki Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nobumasa Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kentaro Sudo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuyuki Kawamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takeshi Kajiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Koushiro Ohtsubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naohiro Okano
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nobuhisa Matsuhashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shinji Itoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Toshihiko Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Satoshi Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Toru Otsuru
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hiroko Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Hiroyuki Okuyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Hideko Ohama
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Toshikazu Moriwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Takashi Ohta
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Justin I. Odegaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Yoshiaki Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Hideaki Bando
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Takayuki Yoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Masafumi Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Chigusa Morizane
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KU and YS contributed to the planning and conducting of studies, recruiting patients, acquisition of data, analysis and interpretation of the data and writing of the manuscript. MF, N Mizuno, KS, YK, TK, KO, NO, N Matsuhashi, SI, T Matsumoto, SS, T Otsuru, HH, H Okuyama, H Ohama, T Moriwaki and T Ohta contributed to the recruitment of patients and acquisition of data. JIO, YN, HB and TY contributed to the planning, conducting of studies and interpretation of data. MU, MI and CM contributed to the recruitment of patients, acquisition of data, planning and interpretation of data. All authors agree to be accountable for all aspects of the work and will ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Yu Sunakawa.

Ethics declarations

Competing interests

MF, KO, N Matsuhashi, SI, T Matsumoto, T Otsuru, HH, H Okuyama and H Ohama have nothing to disclose. KU reports honoraria from Chugai Pharmaceutical, Taiho Pharmaceutical and Yakult Honsha. YS reports honoraria from Takeda Pharmaceutical, Eli Lilly Japan, Chugai Pharmaceutical, Taiho Pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical, Bayer, Daiichi Sankyo and Merck Biopharma; and grants from IQVIA and Parexel; and contributions or endowed chair from Takeda Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Sanofi and EN Otsuka Pharma. MU reports grants and personal fees from Taiho Pharmaceutical, AstraZeneca, Merck Biopharma, MSD, Ono Pharmaceutical, Incyte Corporation and Chugai Pharmaceutical; and personal fees from Nihon Servier; and grants from Astellas Pharma, Eisai and DFP. N Mizuno reports grants and personal fees from AstraZeneca, Novartis, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical; and grants from MSD, Dainippon Sumitomo Pharma, ASLAN Pharmaceuticals, Incyte Corporation. and Seagen; and personal fees from Teijin Pharma, FUJIFILM Toyama Chemical, outside the submitted work. KS reports honoraria from Ono Pharmaceutical and Yakult Honsha; and grants (for the institution) from Bristol-Myers Squibb/Ono Pharmaceutical, Eisai and Incyte corporation. YK reports honoraria from Taiho Pharmaceutical, Incyte, Merck Biopharma, Yakult Honsha, and Eli Lilly; and grants from Takeda Pharmaceutical. TK reports honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical and Eli Lilly. NO reports honoraria from Taiho Pharmaceutical, Eli Lilly, Eisai, Bayer Yakuhin, Chugai Pharmaceutical, Ono Pharmaceutical and Takeda Pharmaceutical; and advisory board from GlaxoSmithKline. SS reports grants from AstraZeneca, Incyte Corporation and Delta-Fly Pharma. T Moriwaki reports honoraria from Taiho Pharmaceutical, Eli Lilly Japan, Takeda Pharmaceutical, Chugai Pharmaceutical, Sanofi, Bayer Yakuhin, Merck Biopharma, Ono Pharmaceutical and Yakult Honsha; and grants from Taiho Pharmaceutical, MSD, Takeda Pharmaceutical, and Yakult Honsha. T Ohta reports honoraria from Chugai Pharmaceutical, Teijin Pharma, Takeda Pharmaceutical, Eisai, Yakult-Honsha, Daiichi Sankyo, Merck Biopharma, Ono Pharmaceutical, Taiho Pharmaceutical and Bristol-Myers Squibb; and grants from Takeda Pharmaceutical. JIO reports from, and stock interests in, Guardant Health. YN reports grants from Taiho Pharmaceutical, Chugai Pharmaceutical, Guardant Health, Genomedia, Daiichi Sankyo, Seagen, Roche Diagnostics. HB reports honoraria from Taiho Pharmaceutical, Eli Lilly Japan, Ono Pharmaceutical; and grants from Ono Pharmaceutical outside the submitted work. TY reports honoraria from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Merck Biopharma, Bayer Yakuhin, Ono Pharmaceutical and MSD; and grants from Ono Pharmaceutical, Sanofi, Daiichi Sankyo, Parexel International, Pfizer Japan, Taiho Pharmaceutical, MSD, Amgen, Genomedia, Sysmex, Chugai Pharmaceutical and Nippon Boehringer Ingelheim. MI reports honoraria from Bayer, Bristol-Myers Squibb, Eli Lilly, Eisai, Sumitomo Dainippon Pharma, EA Pharma, Teijin Pharma, Yakult Honsha, Taiho Pharmaceutical, Otsuka, MSD, Mylan, Nihon Servier, Chugai Pharmaceutical, AstraZeneca, AbbVie, Abbott, Takeda, Novartis and Astellas Pharma; and advisory roles with Bayer, Eli Lilly, Eisai, Chugai Pharmaceutical, AstraZeneca, Takeda Pharmaceutical, Ono Pharmaceutical, GlaxoSmithKline and Nihon Servier; and grants from Bayer, Bristol-Myers Squibb, Eli Lilly, Eisai, Takeda Pharmaceutical, AstraZeneca, Chugai Pharmaceutical, Merck Biopharma, ASLAN Pharmaceuticals, Novartis, Yakult Honsha, Taiho Pharmaceutical, Ono Pharmaceutical, MSD, Merus N.V., Nihon Servier, Pfizer, Chiome Bioscience, Delta-Fly Pharma, and J-Pharma. CM reports honoraria from Nihon Servier, Novartis, Yakult Honsha, Teijin Pharma, Taiho Pharmaceutical, Eisai and MSD; advisory roles with Yakult Honsha, Novartis, Servier, Taiho Pharmaceutical and Abbvie; and grants from Eisai, Yakult Honsha, Ono Pharmaceutical, Taiho Pharmaceutical, J-Pharma, Daiichi Sankyo, HITACHI, AstraZeneca and Merck Biopharma.

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. The protocol of the GOZILA study was approved by the institutional review board of each participating institution and registered at the University Hospital Medical Information Network (UMIN) Clinical Trials Registry (protocol no. UMIN000029315 for GOZILA.

Consent to publish

This manuscript does not contain any individual person’s data such as individual details, images or videos.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Umemoto, K., Sunakawa, Y., Ueno, M. et al. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Br J Cancer 128, 1603–1608 (2023). https://doi.org/10.1038/s41416-023-02189-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-023-02189-y

This article is cited by

Search

Advanced search

Quick links